Natural killer group 2 member D receptor (NKG2D) (NKG2D)

The NKG2D receptor is an activating C-type lectin-like immunoreceptor encoded by KLRK1, expressed on NK cells and subsets of T cells (including CD8+ T, γδ T, and NKT cells), where it mediates direct activation of NK cells and provides co-stimulation to T cells[3][5][6]. NKG2D recognizes a diverse set of stress-inducible MHC class I–like ligands (e.g., MICA/MICB and ULBP family) upregulated on tumor and infected cells, triggering cytotoxic responses—including perforin and granzyme release—and contributing to tumor immune surveillance[1][3][6]. Structurally, NKG2D is a symmetric homodimer that engages monomeric ligands in a 2:1 complex and signals via adaptor molecules because its cytoplasmic tail lacks intrinsic signaling capacity[6][5]. In cancer, tumors frequently evade this pathway by downregulating membrane-bound ligands or shedding soluble ligands (sMICA/B, sULBPs) through ADAM/MMP proteolysis or exosomes, which bind NKG2D, induce its internalization, and diminish NK and CD8+ T-cell functions[2][3]. Although NKG2D can override inhibitory signals and act as a “master switch” for NK activation, sustained ligand exposure in the tumor microenvironment can downregulate NKG2D and reset activation thresholds, making therapeutic manipulation of the NKG2D–ligand axis both promising and complex[1][4][5].

Other names

Killer cell lectin-like receptor subfamily K member 1 (KLRK1)CD314 (cluster of differentiation 314)NKG2-D receptorNatural killer cell receptor NKG2D

Agonism of NKG2D to enhance NK-cell activation and tumor cell killing via recognition of NKG2D ligands (e.g., MICA/B, ULBPs); Blockade of soluble NKG2D ligands (sMICA/B, sULBP) to prevent NKG2D downregulation and restore cytotoxic function; Inhibition of ligand shedding (e.g., ADAM/MMP inhibitors) to increase membrane-bound ligands and enhance recognition; Co-stimulatory signaling in CD8+ T cells to potentiate TCR-mediated responses